Overview

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with placebo and mirabegron distributed in a 1:1 fashion. The patients enrolled will have cardiac structural remodeling with or without symptoms of heart failure (maximum NYHA II). Patients will be monitored for change in left ventricular mass (assessed by cardiac MRI) and/or changes in diastolic function (assessed by echocardiography) after 12 months of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Jean-Luc Balligand

Collaborators:

Center for Cardiovascular Research Berlin
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
European Clinical Research Infrastructure Network
European Commission
European Society of Cardiology
Nantes University Hospital
Northern Lisbon Hospital Center
Papa Giovanni XXIII Hospital
University Medical Center Goettingen
University of Athens
University of Oxford
Wroclaw Medical University
Zentrum für Klinische Studien Leipzig

Treatments:

Adrenergic Agents
Mirabegron